Generic Medicine Info
Indications and Dosage
Male hypogonadism
Adult: 5-20 mg daily.

Delayed male puberty
Child: 2.5-10 mg daily, generally given for 4-6 mth only. Up to 20 mg daily have been used.

Palliative treatment of inoperable neoplasms of the breast in postmenopausal women
Adult: Up to 40 mg daily.
Hypersensitivity; males with breast or prostate carcinoma; serious cardiac, renal or hepatic disease. Pregnancy.
Special Precautions
Cardiac, renal or hepatic dysfunction. Monitor signs of virilization (females) and development of priapism (males). Periodic Hb and haematocrit determinations (high-dose/ long-term therapy). Radiographic exam every 6 mth (prepubertal childn). Child (extreme caution). Lactation. Report too frequent/persistent penile erections; hoarseness, acne, menstrual changes, growth of facial hair (females); nausea, vomiting, changes in skin color, ankle swelling. Discontinue treatment if patient develops jaundice or cholestatic hepatitis. Safety and efficacy of the drug used in enhancing athletic performance is not proven.
Adverse Reactions
Acne, gynaecomastia, oedema, hypersensitivity reactions, hypercalcaemia, cholestatic jaundice, fluid and electrolyte retention, changes in libido, anxiety, depression, accelerated bone maturation, clotting factor suppression, male pattern baldness. Oligospermia and decreased ejaculatory vol (males). Amenorrhoea and other menstrual irregularities, gonadotropin secretion inhibition, virilization (females).
Potentially Fatal: Prolonged use is associated with increased risk of hepatic adenoma, hepatocellular carcinoma and peliosis hepatitis.
Drug Interactions
Potentiate action of oral anticoagulants. Coadministration of oxyphenbutazone and androgens may result in elevated serum levels of oxyphenbutazone.
Lab Interference
Abnormal liver function tests. May decrease protein-bound iodine (PBI) and thyroxine-binding globulin concentrations.
Description: Fluoxymesterone, a synthetic androgenic anabolic steroid hormone, is a halogenated derivative of 17-α-methyltestosterone. It produces nitrogen, K and phosphorus retention; increases protein anabolism; and decreases urinary Ca concentrations, and causes recalcification of osseous metastases and regression of soft tissue lesions.
Disclaimer: This information is independently developed by MIMS based on Fluoxymesterone from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 MIMS. All rights reserved. Powered by MIMS.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in